NORTHAMPTON, MA / ACCESS Newswire / January 22, 2025 / Illumina recently launched the MiSeq i100 and MiSeq i100 Plus Systems, two powerful, compact benchtop sequencers that incorporate more than ...

Over the past year, the shadow of the Grail deal has hung over Illumina despite its reinvigorated leadership and launch of ...

Illumina exhibited stable performance in its latest earnings, meeting revenue estimates while navigating rising expenses and legal costs.

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, has been named for the sixth ...

La empresa local de secuenciación genética citó ahorros de costos para alinearse con su futura estrategia comercial.

In this Innovation Spotlight, Emmanuel Naouri, associate director of Product Management, NGS Benchtop Systems at Illumina, discusses how the MiSeq i100 Series of sequencers was designed to meet the ...

Illumina's innovation pipeline remains a critical factor in its future success. The company recently announced the MiSeq i100 series, which analysts believe could significantly expand Illumina's ...

Massey Genome Service (MGS) has invested in two Illumina MiSeq™ instruments. We offer Illumina MiSeq™ sequencing with the following applications: Send the Massey Genome Service (MSG) an email about ...

Illumina recently launched the MiSeq i100 and MiSeq i100 Plus Systems, two powerful, compact benchtop sequencers that incorporate more than 140 invention disclosures and 60 patent families.

Full or partial Illumina MiSeq runs available for customer created libraries. Additionally plasmids or other double-stranded DNA samples can be submitted for a service called “WideSeq”, WideSeq ...

NORTHAMPTON, MA / ACCESS Newswire / January 22, 2025 / Illumina recently launched the MiSeq i100 and MiSeq i100 Plus Systems, two powerful, compact benchtop sequencers that incorporate more than 140 ...